Introduction
One of the widely held hypotheses on the pathophysiology underlying Alzheimer's disease (AD) is that of a cholinergic deficit in the nucleus basalis of Meynert (Whitehouse et al., 1982; Katzman, 1986) . Pharmacological approaches to providing a palliative treatment for AD have thus been aimed at enhancing transmission at the cholinergic synapses remaining in this region (Reinikainen et al., 1990 ; Kumar & Calache, 1991) . Agents affecting the cholinergic system which have been examined with varying success include arecoline (Christie, 1982) , bethanechol (Penn et al., 1988; Read et al., 1990) , physostigmine (Muramoto et al., 1984; Harrell et al., 1990) , and tetrahydroaminoacridine (THA) (Summers et al., 1986; Molloy et al., 1991) . Agents which have received more serious consideration are Synapton, a controlled release physostigmine (Forest Labs), Cognex, a formulation of THA (Warner-Lambert), Mentane, a THA analogue (HoechstRoussel), and HP 290, an analogue of physostigmine (Hoechst-Roussel) (reviewed by Sarter, 1991) .
Linopirdine or DuP 996 (3,3-bis(4-pyridinylmethyl)-1-phenylindolin-2-one, Du Pont Merck) is a compound currently undergoing Phase III testing for possible use in the treatment of AD. Preclinical studies have shown that DuP 996 enhances the K+-evoked release of acetylcholine (ACh), dopamine and 5-hydroxytryptamine (5-HT) in brain slices, ' Author for correspondence.
without affecting the resting release of these transmitters . A similar increase in ACh release has been seen in synaptosomes (Vickroy, 1993) . The ability to release ACh is highly correlated with the affinities of DuP 996 and thirty of its analogues for specific receptors (Tam et al., 1991) located in areas of the brain associated with cognition (De Souza et al., 1992) . DuP 996 also enhances the performance of rats in behavioural tests and increases the amount of their alpha and beta wave activity recorded with EEGs .
Recent studies with rodent skeletal muscle have shown that
DuP 996 increases the direct and indirect twitch, the miniature endplate potential (m.e.p.p.) frequency, and the quantal content of the endplate potential (e.p.p.) in Mg2'-depressed preparations (Tsai et al., 1992 We have examined the effect of DuP 996 using a new method for obtaining the quantal -release parameters, m (number of quanta released), n (number of functional release sites), p (probability of release), and varsp (spatial variance in p) (Provan & Miyamoto, 1993a) . This approach circumvents the problem of nonuniformity and nonstationarity in the quantal estimates (Brown et al., 1976) , as well as the problem of inaccuracies in the nerve-evoked synaptic potential (Zucker, 1977) . The aims of this study were (a) to examine whether DuP 996 produces a significant increase in quantal ACh release, as monitored by the release parameters, and (b) to elucidate the cellular or subcellular mechanism by which DuP 996 enhances neurosecretion. A preliminary account of these results was presented at the 1992 Meeting of the American Society for Pharmacology and Experimental Therapeutics in Orlando, FL (Provan & Miyamoto, 1992 (Provan & Miyamoto, 1993a) . The control solution thus contained (in mM): NaCl 102.5, KCl 10.0, CaCl2 1.8, Tris 2.0 (adjusted to pH 7.2), and glucose 5.6. Muscles were equilibrated for at least 30 min before use, to allow re-establishment of the Donnan equilibrium and ensure that results were obtained during the longterm, steady-state effect of K+ (Cooke & Quastel, 1973 (Hille, 1984 Data collection, analysis and statistics Specific details of the overall procedure-are described elsewhere (Provan & Miyamoto, 1993a) . Briefly, the number of quanta released by one nerve impulse (m) was replaced by the number of m.e.p.ps occurring in a 50 ms time interval (bin), and 500 sequential bins were used for each estimate. Data were divided into subgroups of 100 before analysis to minimize nonstationarity, and results which were nonst~t-ionary according to statistical tests were discarded. Unbiaied estimates of m, n, p, and varsp were then computed by use of equations previously reported (Miyamoto, 1986) .
M.e.p.p. amplitudes were obtained from digitized data and adjusted for baseline fluctuations with a double vertical cursor tool. Results were corrected for shifts in membrane potential (Katz & Thesleff, 1957) , after recalculating the reversal potential for ionic changes in the solution (Takeuchi, 1963) . The number required for each estimate was determined by collecting 500 m.e.p.ps and designating the mean amplitude as the 'control'. These were then divided into subgroups of 50, and the means of the cumulative subgroups plotted as percentages of control. A sample size of two subgroups (100 m.e.p.ps) was found to be sufficient, since accuracy was not improved with the use of more subgroups.
Results were obtained from 5-6 different preparations for each experimental procedure. In several instances, data were converted to percentage of control and then averaged, to illustrate better the percentage increase or decrease. In these cases, the values equal to 100% are given in the Figure  legends . One-way analysis of variance (ANOVA) was used to test for differences between groups of data, with P <0.05 chosen as the level of significance. Results are expressed as means ± s.e.mean.
Results

Effect of DuP 996 at K+-depolarized nerve terminals
The first step was to find a working concentration of DuP 996. Junctions were selected as described, and m.e.p.ps recorded every 5 min. DuP 996 was added to the bath starting at 0.1 JAM, and recordings made after 15 min. The concentration was then increased in half-logarithmic increments (0.3, 1, 3 JM, etc.), and the response recorded after another 15 min.
The time course of effect (onset, peak, and reversal) was found to be basically the same for each concentration tested, and the concentration finally used was 1O JAM. An illustration of the response is presented in Figure 1 , in which sample records of m.e.p.ps are shown for control (Figure la (Figure 2a ) was, according to the method of Provan & Miyamoto (1993a) , equivalent to an increase in m. This increase in m could in turn be due to an increase in n, p, or both n and p (since m = np). To dissociate the effect on m into its quantal components and examine the temporal relationships of the changes, data were recorded for 15 min in Values for m and n are in quanta, whereas p and varp are dimensionless. Points represent means ± s.e.mean of six separate experiments.
As before (Figure 2a ), the effect of DuP 996 on m occurred rapidly, with a peak increase after 10 min and a plateau thereafter (Figure 3a ). There were also immediate increases in n and p (Figure 3b, c) , which meant that the increase in m was due to increases in both parameters. By the end of 60 min exposure to DuP 996, there was a slight decrease in n (Figure 3b ). This was offset by a small increase in p (Figure  3c ), so the net effect was a sustained increase in m ( Figure  3a) (the decrease in n may have been due to a reduced number of available quanta during the prolonged release of transmitter). On washing with control solution, the increases in n and p, like that for m, returned to control levels within 15 min (Figures 3a-c) . By contrast, DuP 996 produced no significant changes in varsp (Figure 3d ).
Concentration-dependent effects of DuP 996 on unbiased quantal release parameters
The effect of [DuP 996] on m, n, p and varp was examined to provide information on (a) the threshold concentration which elicited a response, (b) the nature of the concentration-effect relationship, and (c) whether desensitization or inhibition occurred at the higher levels.
Junctions were sequentially exposed to half-logarithmic increments of [DuP996] from 0.1 to 100 AM, and m.e.p.ps recorded after 15 min exposure to each concentration (as the response took 10-15 min to reach plateau). The combined results from six experiments showed concentration-dependent increases in m, n and p (Figures 4a-c) , with the threshold effect occurring at 0.3 ILM (Figure 4a ). The effect on p appeared to peak at [DuP 996] >I1 M (Figure 4c) , such that the increase in m at this level was due primarily to an increase in n (Figure 4b ). The 50% effective concentration (EC50) for p (using 4-parameter logistic curve-fitting) was 1.1 1AM (equivalent EC50 could not be determined accurately for m and n since these curves did not saturate). Lastly, increasing [DuP 996] produced no significant effects on varsp (Figure 4d ), except for a modest increase at the highest concentration examined (100 tM).
Effect ofw-conotoxin GVIA (w-CgTX) on the increase in quantal release produced by DuP 996 The effect of w-CgTX, an irreversible N-type Ca2"-channel blocker (Sher & Clementi, 1991) (Bowman et al., 1977 and Figure 6 ) and on synaptic delay (Molgo et al., 1977) .
To examine the effect of voltage-gated K+-channel block on the response to DuP 996, recordings were carried out for 20 min in control solution, 50 min in 100 tM 4-AP, 30 min in 00 gM 4-AP plus 10 gM DuP 996, and 25 min during wash ( Figure 7 ). As before (Figure 6) (Figures 2a, 5) . The increase in m was due to an increase in n (Figure 7b ), as both p and varsp were unchanged (Figures 7c, d ). (Harvey, 1993) ). One way of differentiating between these two mechanisms was to examine the effect of DuP 996 after voltage-gated K'-channels were completely blocked, e.g., with supramaximal concentrations of 4-AP (Lundh, 1978 ). An increase in transmitter release under these circumstances would then indicate that the effect of DuP 996 could not have been due to block of voltage-gated K'-channels. .. 
Discussion
Unbiased estimates of quantal release parameters The present study uses a new procedure which avoids the problem of nonuniformity and nonstationarity (Brown et al., 1976) to obtain unbiased estimates of n and p (Provan & Miyamoto, 1993a) . Important features of the method are the use of direct quantal counts (m.e.p.ps) and elevated K+ to evoke transmitter release. Direct counting of quanta eliminates the need to measure e.p.p. amplitudes, which may give inaccurate estimates of m (Zucker, 1977) and which may reflect, at least in theory, both quantal and non-quantal release (Zemkovat et al., 1990) . Use of elevated K+ mimics the conditions used in measuring total ACh release, thereby allowing a more direct comparison between results obtained for quantal and total ACh release.
Comparison of results with neurochemical studies
The present findings are in basic agreement with those of neurochemical studies which monitored K+-stimulated ACh release in brain slices and synaptosomes (Vickroy, 1993) . For example, DuP 996 was found to produce a sizeable increase in quantal ACh release (Figures 1, 2a, 3-5) , which was consistent with the increase in total (quantal plus non-quantal) ACh release found by Nickolson et al. (1990) . Second, the threshold concentration for the effect on m was 0.3 pM (Figure 4a) , which compared favourably with the 0.1 to 1 pM range found for brain slices (Table 1 of Nickolson et al., 1990) and synaptosomes (Figures 2-4 of Vickroy, 1993) . Third, the increase in m (to 300% of control with 100 1M, Figure 4a ) was comparable to the average increase in ACh release for cortex, hippocampus, and caudate nucleus (to 335% of control with 100 jaM; Table   1 of Nickolson et al., 1990 ) and for hippocampal synaptosomes (to 260% of control with 30 gm; Figures 3, 4 of Vickroy, 1993) . Finally, the effect of DuP 996 on m, n and p was readily reversible (Figures 2a, 3a, 7) , which was consistent with the notion of a saturable, reversible binding to a specific receptor site (Tam et al., 1991 (Figures 2a, 3a, 7) , and the time course of onset is similar to that for washout. Both these findings are compatible with an extracellular rather than an intracellular site of action. Second, the effect of DuP 996 is reversibly inhibited by TTX and Co2" (Figure   2b ), which suggests that the action must occur at, or prior to, influx of Ca2" at the membrane. Third, the effect of DuP 996 is rapidly and irreversibly blocked by co-CgTX ( Figure 5 ). This indicates the site of action may be at, or near, the voltage-gated Ca2"-channel. Fourth, DuP 996 does not produce an increase in varsp (Figures 3d, 4d, 7d) . According to recent studies (Provan & Miyamoto, 1993a) , and it does not involve histamine, benzodiazepines, opioids, or a variety of peptides (Tam et al., 1991) .
DuP 996 does not act by inhibiting voltage-gated K+-conductance, because (a) block with 4-AP produces only a small increase in m.e.p.p. frequency (Figures 6, 7a) , and (b) the effect of DuP 996 is not prevented by prior block with 4-AP (Figure 7a ). These findings coincide with the report that DuP 996 does not inhibit voltage-gated K+-channels . A block of calcium-activated K+-channels by DuP 996 is unlikely, because block of these channels with charybdotoxin produces no increase in m.e.p.p. frequency (Robitaille & Charlton, 1992) . Finally, block of K+-channels would have been manifested by a prolongation of the nerve action potential, which is not observed with DuP 996 (Tsai et al., 1992) .
This means that DuP 996 works by depolarizing the presynaptic membrane or by increasing Ca2"-channel conductance. While we cannot at present differentiate between these two possibilities, we tend to favour the latter explanation.
The results with w-CgTX ( Figure 5 ) suggest that DuP 996 promotes the influx of Ca2" through N-type Ca2-channels.
If this is so, it may be that the action is not specific for a particular type of Ca2+-channel, since ACh release at mammalian junctions, which is not mediated by N-type-Ca2+-channels (Wray & Porter, 1993) , is also enhanced by DuP 996 (Tsai et al., 1992) . The increase in m which results from 4-AP plus DuP 996 (Figure 7a ) is of interest for two reasons: first, the increase is due solely to an increase in n (Figure 7) , which is what is found with tetraethylammonium (Volle & Branisteanu, 1976) and guanidine derivatives (Volle & Branisteanu, 1976; Farley et al., 1979 ) using nerve-evoked e.p.ps and biased estimates of n and p. Second, assuming that DuP 996 increases Ca2"-channel conductance, the finding of a supra-additive response with 4-AP would be compatible with the idea of overlapping effects of Ca2+ and K+ channels at the active zone (cf. Robitaille et al., 1993) .
DuP 996 does not alter postsynaptic sensitivity DuP 996 produced no significant change in m.e.p.p. amplitude, and no visible change in m.e.p.p. rise time or decay (e.g., Figure 1 ). Accordingly, DuP 996 must have produced little or no ChE inhibition, which is in agreement with the neurochemical findings . This lack of effect differs from the increases in m.e.p.p. amplitude found with 3 jM THA (22%), physostigmine (46.5%) and neostigmine (79.2%) (Provan & Miyamoto, 1991) , all of which are known antiChEs. This again implies that the facilitatory action of DuP 996 on cholinergic transmission must be due to pre-and not postsynaptic effects.
Potential advantages of DuP 996 as a palliative treatment for AD One way of enhancing cholinergic transmission in AD is to inhibit ChE. However, chronic administration of antiChEs may produce receptor desensitization, so an alternative is to increase ACh release at the remaining nerve terminals, using agents such as DuP 996. The finding of an increase in quantal ACh release with DuP 996 affirms that the increase in ACh output is not due to interference with quantal packaging and overflow of non-quantal ACh, as may occur with physostigmine (Alderdice, 1979; Provan & Miyamoto, 1991 ).
An agent used in the treatment of AD should work by accelerating existing processes and not by inhibiting cellular components. Agents known to inhibit mitochondrial function, e.g., La3+, Hg+, methyl Hg+, and flufenamic acid, have been found to increase p and varsp (Provan & Miyamoto, 1993a,b) . Accordingly, the finding that DuP 996 does not alter varsp is important, since it implies that facilitation of ACh release is probably not due to mitochondrial inhibition. The absence of such adverse effects would be advantageous for DuP 996 or any other agent relegated to long-term clinical use.
